U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N.ClH
Molecular Weight 185.694
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTERMINE HYDROCHLORIDE

SMILES

Cl.CC(C)(N)CC1=CC=CC=C1

InChI

InChIKey=NCAIGTHBQTXTLR-UHFFFAOYSA-N
InChI=1S/C10H15N.ClH/c1-10(2,11)8-9-6-4-3-5-7-9;/h3-7H,8,11H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula C10H15N
Molecular Weight 149.2328
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

CNS Activity

Originator

Approval Year

1959
136
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 0.31 µM [EC50]
Inhibitor
8146
 498.0 µM [Ki]
Inhibitor
8146
 375.0 µM [Ki]
Inhibitor
8146
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
ADIPEX-P

Approved Use

ADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors

Launch Date

-3.47241611E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.78 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49.1 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2057.33 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2000 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.63 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Abdominal pain, Dizziness...
Other AEs:
Abdominal pain (6%)
Dizziness (6%)
Early satiety (6%)
Intermittent headache (6%)
Nausea (6%)
Swollen lips (6%)
Upper respiratory infection (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Anorexia, Back pain...
Other AEs:
Anorexia (6%)
Back pain (6%)
Chapped lips (6%)
Dry skin (6%)
Dyspepsia (6%)
Early satiety (6%)
Irregular pulse (6%)
Nausea (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Other AEs: Tachycardia, Hypertension...
Other AEs:
Tachycardia
Hypertension
Visual disorders NEC
Nausea
Insomnia
Anxiety
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disc. AE: Amnesia, Judgement impaired...
Other AEs: Disorder sleep, Depression...
AEs leading to
discontinuation/dose reduction:
Amnesia (0.3%)
Judgement impaired (0.3%)
Memory impairment (0.3%)
Paraesthesia (0.3%)
Depression (1%)
Anxiety (0.3%)
Vision blurred (0.3%)
Eye pain (0.3%)
Abdominal pain (0.3%)
Tuberculosis skin test positive (0.3%)
Nephrolithiasis (0.3%)
Other AEs:
Disorder sleep (12.9%)
Depression (8.1%)
Anxiety (9.5%)
Cardiac arrhythmia (4.1%)
Ischemic heart disease (1%)
Disturbance in attention (3.1%)
Memory impairment (2%)
Cognitive disorders (1.4%)
Language disorder (0.3%)
Ocular disorders NEC (4.1%)
Dyskinesias and movement disorders NEC (1.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dizziness 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Intermittent headache 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Swollen lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Upper respiratory infection 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anorexia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Back pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Chapped lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dry skin 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dyspepsia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Irregular pulse 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anxiety
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Hypertension
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Insomnia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Nausea
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Tachycardia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Visual disorders NEC
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Language disorder 0.3%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Abdominal pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Amnesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Eye pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Judgement impaired 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Nephrolithiasis 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Paraesthesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Tuberculosis skin test positive 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Vision blurred 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ischemic heart disease 1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 1%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cognitive disorders 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Dyskinesias and movement disorders NEC 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disorder sleep 12.9%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disturbance in attention 3.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cardiac arrhythmia 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ocular disorders NEC 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 8.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 9.5%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1532

substrate
1670
inhibitor
1695
inhibitor
1789

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1463

CYP2E1
846
CYP
76
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP
143
 no
CYP1A2
1620
 no
CYP2C9
1747
 no
CYP2D6
1826
 no
CYP2E1
929
 no
CYP3A4
1857
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1670
 major
weak (co-administration study)
Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively
Page: 39,38
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8080
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8080
ZINC
ZINC000008403947
http://zinc15.docking.org/substances/ZINC000008403947
eMolecules
1846375
https://www.emolecules.com/cgi-bin/more?vid=1846375
PubMed

PubMed

TitleDatePubMed
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
1999 Dec
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
1999 Dec 1
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
1999 Jul
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension.
1999 Jun
Pharmaceutical cost savings of treating obesity with weight loss medications.
1999 Nov
Histologic changes in three explanted native cardiac valves following use of fenfluramines.
1999 Sep-Oct
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
2000 Apr 5
[Obesity: principles of drug therapy].
2000 Aug
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramin.
2000 Jun
Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
2000 May 2
Silver lining to the cloud over anorexogen-related cardiac valvulopathy?
2001 Feb 20
Pharmacologic options for the treatment of obesity.
2001 Jul 15
A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule.
2001 Mar 1
Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report.
2001 May
Fenfluramine and phentermine.
2001 Nov 6
Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices.
2001 Nov-Dec
Drug treatment of obesity.
2001 Oct
High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label.
2001 Oct
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
2001 Oct 24-31
Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol.
2001 Sep
Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
2001 Sep
Pharmacotherapy of obesity: currently marketed and upcoming agents.
2002
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
2002
Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go.
2002 Aug
Appetite suppressants and valvular heart disease - a systematic review.
2002 Aug 23
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
2002 Dec 1
[Syncope - a systematic overview of classification, pathogenesis, diagnosis and management].
2002 Feb
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.
2002 Jun 7
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe?
2002 May
Prevalence of drug use in commercial tractor-trailer drivers.
2002 May
Noradrenergic modulation of ephedrine-induced hypophagia.
2003 Apr
Obesity.
2003 Dec
Medical monitoring for pharmaceutical injuries: tort law for the public's health?
2003 Feb 19
Obesity drug pipeline not so fat.
2003 Feb 7
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats.
2003 Jul 5
Risk of valvular heart disease associated with use of fenfluramine.
2003 Jun 11
Malpractice. Conviction upheld for doctor who treated AIDS with fen/phen.
2003 May 9
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment.
2004 Dec
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
2004 Dec
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY.
2004 Jan
Pharmacological and surgical treatment of obesity.
2004 Jul
Taking things to heart.
2004 Jul
Obesity.
2004 Jun
The long-term management of obesity with continuing pharmacotherapy.
2004 Nov
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
2005 Jan 25
Patents

Patents

05536714
5
05698720
5
05808071
2
06376555
2
JP2001172180A
3
JP2005531585A
19

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Weight Loss 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast. Usual Pediatric Dose for Weight Loss 17 years or older: 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration: Oral
In Vitro Use Guide
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:12:44 UTC 2022
Edited
by admin
on Fri Dec 16 16:12:44 UTC 2022
Record UNII
0K2I505OTV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENTERMINE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
PHENTERMINE HYDROCHLORIDE [MI]
Common Name English
OBESTIN-30
Brand Name English
Phentermine hydrochloride [WHO-DD]
Common Name English
PHENTERMINE HYDROCHLORIDE CIV
USP-RS  
Common Name English
PHENTERMINE HYDROCHLORIDE [VANDF]
Common Name English
?,?-Dimethylphenethylamine hydrochloride
Systematic Name English
FASTIN
Brand Name English
QSYMIA COMPONENT PHENTERMINE HYDROCHLORIDE
Brand Name English
PHENTERMINE HYDROCHLORIDE COMPONENT OF QSYMIA
Brand Name English
OBY-TRIM
Brand Name English
PHENTERMINE HCL
Common Name English
NSC-44090
Code English
PHENTERMINE HYDROCHLORIDE [MART.]
Common Name English
SUPRENZA
Brand Name English
ADIPEX-P
Brand Name English
PHENTERMINE HYDROCHLORIDE [USP-RS]
Common Name English
ONA-MAST
Brand Name English
TORA
Brand Name English
PHENTERMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
ZANTRYL
Brand Name English
PHENTERMINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
BENZENEETHANAMINE, .ALPHA.,.ALPHA.-DIMETHYL-, HYDROCH
Common Name English
WILPO
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29728
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
DEA NO. 1640
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
Code System Code Type Description
ChEMBL
CHEMBL1574
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
DRUG BANK
DBSALT000138
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
MERCK INDEX
M8644
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY Merck Index
DAILYMED
0K2I505OTV
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
FDA UNII
0K2I505OTV
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
EPA CompTox
DTXSID20152550
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
RXCUI
82078
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY RxNorm
NCI_THESAURUS
C29361
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
RS_ITEM_NUM
1528501
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
PUBCHEM
70969
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
NSC
44090
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
CHEBI
50506
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
ECHA (EC/EINECS)
214-821-9
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
CAS
1197-21-3
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
EVMPD
SUB03767MIG
Created by admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
PRIMARY
Related Record Type Details
Structure of PHENTERMINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PHENTERMINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966